# PDGFRA exon 18 mutation (D842V)

Source: https://onco.cc/biomarkers/pdgfra-exon-18-d842v/  
OnCo record `pdgfra-exon-18-d842v` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PDGFRA D842V drives about 5 percent of gastrointestinal stromal tumours and is resistant to imatinib. Avapritinib is the approved drug for GISTs with PDGFRA exon 18 mutations including D842V.

## Summary

Exon 18 mutations sit in the activation loop; D842V, the commonest, stabilises the active kinase and blocks imatinib, sunitinib and regorafenib binding. Avapritinib (Ayvakit, 2020) is labelled for unresectable or metastatic GIST harbouring a PDGFRA exon 18 mutation, including D842V, and the therascreen PDGFRA RGQ PCR Kit is its companion diagnostic (P210002, 2023). Non-D842V exon 18 mutations remain partly imatinib-sensitive, so the exact variant is reported.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: PDGFRA D842V; D842V; PDGFRA exon 18; PDGFRA exon 18 mutation; PDGFRA-mutant GIST
- Tags: biomarker; gist

## Sources

- AYVAKIT prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9

## Connected records

- biomarkers: [KIT D816V](https://onco.cc/biomarkers/kit-d816v/)
- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [PDGFRA D842V-mutant GIST](https://onco.cc/cancers/gist-pdgfra-d842v/)
- drugs: [Avapritinib](https://onco.cc/drugs/avapritinib/), [Imatinib](https://onco.cc/drugs/imatinib/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/)
- terms: [GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)](https://onco.cc/terms/gist-risk-stratification/)
- targets: [PDGFRA](https://onco.cc/targets/pdgfra/)

---
JSON: https://onco.cc/api/v1/entities/pdgfra-exon-18-d842v.json